Seeking Alpha

Keryx Pharmaceuticals (KERX) +12.4% premarket, enjoying a boost from two analyst buy...

Keryx Pharmaceuticals (KERX) +12.4% premarket, enjoying a boost from two analyst buy recommendations. Ladenburg Thalmann notes data from the long-term Phase 3 study of hyposphatemia drug Zerenex (data expected in Q4) represents a "significant event" for KERX. Roth Capital raises its target price on the shares to $7 from $4.
From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs